PD-1抗体与抗血管生成药物分别联合化疗治疗晚期驱动基因阴性肺腺癌的近远期效果对比  

Comparison of short-term and long-term effects of PD-1 antibody or anti-angiogenic drug combined with chemotherapy on driver gene-negative advanced lung adenocarcinoma

作　　者：李丹青 张少锋 张芬 焦会茹 牛立梅 杨立鑫[1] 张钦 LI Dan-qing;ZHANG Shao-feng;ZHANG Fen;JIAO Hui-ru;NIU Li-mei;YANG Li-xin;ZHANG Qin(Department of Tumor Radiotherapy,Xingtai People's Hospital,Xingtai 054031,Hebei,China;Department of Thoracic Surgery,Xingtai People's Hospital,Xingtai 054031,Hebei,China)

机构地区：[1]邢台市人民医院肿瘤放射治疗科,河北邢台054031 [2]邢台市人民医院胸外科,河北邢台054031

出　　处：《川北医学院学报》2024年第7期896-899,共4页Journal of North Sichuan Medical College

基　　金：河北省自然科学基金资助项目(H2022206546)。

摘　　要：目的:比较程序性细胞死亡受体-1(PD-1)抗体与抗血管药物分别联合化疗治疗晚期驱动基因阴性肺腺癌的近远期效果。方法:选取118例晚期驱动基因阴性肺腺癌患者为研究对象,根据不同治疗方式将PD-1抗体联合化疗的患者纳入A组(n=60);将抗血管生成药物联合化疗的患者纳入B组(n=58)。观察两组患者临床近期疗效,毒副反应,免疫功能和预后分析。结果:治疗后,A组患者近期临床疗效的客观有效率(ORR)、疾病控制率(DCR)和疾病无进展期(PFS)明显高于B组(P<0.05);两组患者CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均上升(P<0.05),且A组高于B组(P<0.05);CD8^(+)水平均降低,且A组低于B组(P<0.05);A组患者和B组患者治疗期间毒副反应发生率无统计学差异(P>0.05)。结论:PD-1抗体联合化疗治疗晚期驱动基因阴性肺腺癌患者临床疗效更好,有助于恢复免疫功能,且毒副反应少,具有良好的安全性,有助于延长PFS,值得临床推广应用。Objective:To compare the short-term and long-term effects of programmed cell death receptor-1(PD-1)antibody or anti-angiogenic drug combined with chemotherapy in the treatment of driver gene-negative advanced lung adenocarcinoma.Methods:118 patients with driver gene-negative advanced lung adenocarcinoma were selected as the research subjects,they were divided into group A(treated with PD-1 antibody combined with chemotherapy,n=60)and group B(treated with anti-angiogenic drug combined with chemotherapy,n=58)according to different treatment methods.The short-term clinical efficacy,toxic and side effects,immune function and prognosis were observed in both groups.Results:In terms of short-term clinical efficacy,the objective response rate(ORR),disease control rate(DCR)and progression-free survival(PFS)were higher in group A after treatment compared to group B(P<0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in both groups were risen compared with those before treatment(P<0.05),and the levels in group A were higher than those in group B(P<0.05).The level of CD8^(+)was reduced in the two groups after treatment than that before treatment,and the CD8^(+)in group A was lower than that in group B(P<0.05).There were no obvious differences in the toxic and side effects between A groups and B groups during treatment(P>0.05).Conclusion:PD-1 antibody combined with chemotherapy has good clinical efficacy in treating patients with driver gene-negative advanced lung adenocarcinoma.It can help to restore theimmune function,and it has few toxic and side effect and good safety and is helpful to prolong PFS,which is worthy of clinical promotion and application.

关 键 词：PD-1抗体 抗血管生成药物 驱动基因阴性 晚期肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]